Floatz logo

Eptinezumab

Headache Disorders, Primary

Beijing Tiantan Hospitalmonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Headache Disorders, Primary cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G, ANTI-(HUMAN CALCITONIN GENE-RELATED PEPTIDE RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER
Beijing Tiantan Hospital
Phase 2B
Yangxue Qingnao Granules
Beijing Tiantan Hospital
D
Doxycycline
The Cleveland Clinic
N/AD
Amylin
Danish Headache Center
N/AD
Glyceryl Trinitrate
Leiden University Medical Center
N/AD

Same molecule, other indications

Eptinezumab is also rated in:

migraine disorderDormant
BBB
Indicative ·
79 / 100
View asset →
Medication Overuse HeadacheDormant
BBB
Indicative ·
78 / 100
View asset →
Migraine Associated VertigoDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →